Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics (NASDAQ: STIM) has announced the granting of inducement awards consisting of Restricted Stock Units (RSUs) representing 24,750 shares of common stock to three new non-executive employees. The awards were approved by the company's Compensation Committee in compliance with NASDAQ Listing Rule 5635(c)(4).
The RSU grants have different vesting schedules: three grants will vest in equal installments over three years on the first, second, and third anniversaries of the grant date, while one grant will vest over four years on the second, third, and fourth anniversaries. All grants are contingent upon continued employment with the company through the vesting dates and are subject to the Neuronetics 2020 Inducement Plan terms.
Neuronetics (NASDAQ: STIM) ha annunciato l'assegnazione di premi di induzione costituiti da Unità di Azioni Riservate (RSU) che rappresentano 24.750 azioni ordinarie a tre nuovi dipendenti non esecutivi. I premi sono stati approvati dal Comitato per la Compensazione dell'azienda in conformità con la Regola di Quotazione NASDAQ 5635(c)(4).
Le concessioni di RSU hanno diversi programmi di maturazione: tre concessioni matureranno in rate uguali su tre anni, nelle date del primo, secondo e terzo anniversario della data di concessione, mentre una concessione maturerà su quattro anni, nelle date del secondo, terzo e quarto anniversario. Tutte le concessioni sono subordinate alla continuazione dell'impiego con l'azienda fino alle date di maturazione e sono soggette ai termini del Piano di Induzione Neuronetics 2020.
Neuronetics (NASDAQ: STIM) ha anunciado la concesión de premios de inducción que consisten en Unidades de Acciones Restringidas (RSUs) que representan 24,750 acciones ordinarias a tres nuevos empleados no ejecutivos. Los premios fueron aprobados por el Comité de Compensación de la empresa de acuerdo con la Regla de Cotización 5635(c)(4) de NASDAQ.
Las concesiones de RSU tienen diferentes cronogramas de adquisición: tres concesiones se adquirirán en cuotas iguales durante tres años en el primer, segundo y tercer aniversario de la fecha de concesión, mientras que una concesión se adquirirá durante cuatro años en el segundo, tercer y cuarto aniversarios. Todas las concesiones están sujetas a la continuación del empleo con la empresa hasta las fechas de adquisición y están sujetas a los términos del Plan de Inducción Neuronetics 2020.
Neuronetics (NASDAQ: STIM)는 24,750주에 해당하는 제한 주식 단위(RSU)로 구성된 유인 보상을 세 명의 새로운 비임원 직원에게 부여했다고 발표했습니다. 이 보상은 NASDAQ 상장 규칙 5635(c)(4)에 따라 회사의 보상 위원회에서 승인되었습니다.
RSU 부여는 서로 다른 취득 일정이 있습니다: 세 개의 부여는 부여 날짜의 첫 번째, 두 번째 및 세 번째 기념일에 걸쳐 3년 동안 동일한 할부로 취득되며, 하나의 부여는 두 번째, 세 번째 및 네 번째 기념일에 걸쳐 4년 동안 취득됩니다. 모든 부여는 취득 날짜까지 회사에 계속 고용되는 것에 따라 달라지며, Neuronetics 2020 유인 계획의 조건에 따릅니다.
Neuronetics (NASDAQ: STIM) a annoncé l'octroi de primes d'incitation sous la forme d'Unités d'Actions Restreintes (RSU) représentant 24 750 actions ordinaires à trois nouveaux employés non exécutifs. Les primes ont été approuvées par le Comité de Rémunération de l'entreprise conformément à la Règle d'Inscription NASDAQ 5635(c)(4).
Les attributions de RSU ont des calendriers d'acquisition différents : trois attributions seront acquises par versements égaux sur trois ans lors du premier, deuxième et troisième anniversaire de la date d'attribution, tandis qu'une attribution sera acquise sur quatre ans lors du deuxième, troisième et quatrième anniversaires. Toutes les attributions sont soumises à la poursuite de l'emploi au sein de l'entreprise jusqu'aux dates d'acquisition et sont soumises aux termes du Plan d'Incitation Neuronetics 2020.
Neuronetics (NASDAQ: STIM) hat die Gewährung von Anreizprämien angekündigt, die aus Restricted Stock Units (RSUs) bestehen und 24.750 Aktien des Stammkapitals an drei neue nicht-executive Mitarbeiter repräsentieren. Die Prämien wurden vom Vergütungsausschuss des Unternehmens gemäß der NASDAQ-Listing-Regel 5635(c)(4) genehmigt.
Die RSU-Zuweisungen haben unterschiedliche Vesting-Zeitpläne: Drei Zuweisungen werden in gleichen Raten über drei Jahre am ersten, zweiten und dritten Jahrestag des Zuweisungsdatums fällig, während eine Zuweisung über vier Jahre am zweiten, dritten und vierten Jahrestag fällig wird. Alle Zuweisungen sind an die Fortsetzung der Beschäftigung bei dem Unternehmen bis zu den Vesting-Daten gebunden und unterliegen den Bedingungen des Neuronetics 2020 Anreizplans.
- None.
- None.
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 24,750 shares of the Company’s common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
Three of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, and one of RSU grants vests ratably in equal installments on the second, third and fourth anniversary of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date. The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
About Neuronetics and Greenbrook
Neuronetics, Inc. (“Neuronetics”) believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations by offering exceptional treatments that produce extraordinary results. Neuronetics’ NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar system and associated treatment sessions to customers, Greenbrook TMS Inc. (“Greenbrook”) operates treatment centers across the United States, offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or “TMS”) and Spravato® (esketamine nasal spray) for the treatment of major depressive disorder (“MDD”) and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered and is backed by the largest clinical data set of any TMS treatment system for depression, including the world’s largest depression outcomes registry. Spravato® is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. Greenbrook has provided more than 1.68 million treatments to over 51,000 patients struggling with depression.
Investor Contact:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
FAQ
How many shares of Neuronetics (STIM) were granted as RSUs in March 2025?
What is the vesting schedule for Neuronetics (STIM) RSU inducement grants announced in March 2025?
How many new employees received RSU inducement grants from Neuronetics (STIM)?
Under which plan are the Neuronetics (STIM) RSU inducement grants administered?
